These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 24916728)

  • 21. The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms.
    Sugawara N; Yasui-Furukori N; Tsuji T; Hayashi S; Ajisawa Y; Ochiai T; Imagawa H; Shimoda K
    Neuropsychiatr Dis Treat; 2020; 16():3063-3070. PubMed ID: 33335397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East.
    Hong J; Novick D; Moneta MV; El-Shafei A; Dueñas H; Haro JM
    Clin Pract Epidemiol Ment Health; 2017; 13():145-155. PubMed ID: 29238391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study.
    Yuan H; Zhu X; Luo Q; Halim A; Halim M; Yao H; Cai Y; Shi S
    Neuropsychiatr Dis Treat; 2019; 15():957-966. PubMed ID: 31354272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction.
    Berlin I; Lavergne F
    Eur Psychiatry; 1998 May; 13(3):138-42. PubMed ID: 19698616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinsonism secondary to duloxetine use: a case report.
    Bayrak A; Cetin B; Meteris H; Kesebir S
    North Clin Istanb; 2015; 2(3):243-246. PubMed ID: 28058376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective serotonin reuptake inhibitor combined with dengzhanshengmai capsule improves the fatigue symptoms: a 12-week open-label pilot study.
    Li DQ; Li ZC; Dai ZY
    Int J Clin Exp Med; 2015; 8(7):11811-7. PubMed ID: 26380022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute dystonia after using single dose duloxetine: case report.
    Karakaş Uğurlu G; Onen S; Bayındırlı D; Cayköylü A
    Psychiatry Investig; 2013 Mar; 10(1):95-7. PubMed ID: 23483133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duloxetine-induced liver injury in patients with major depressive disorder.
    Kang SG; Park YM; Lee HJ; Yoon B
    Psychiatry Investig; 2011 Sep; 8(3):269-71. PubMed ID: 21994516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder.
    Haider M; Shafqat MN
    Neuropsychiatr Dis Treat; 2017; 13():2505-2508. PubMed ID: 29042779
    [No Abstract]   [Full Text] [Related]  

  • 30. Review: little evidence to support dose escalation of selective serotonin reuptake inhibitors in non-responders.
    Heres S; Kissling W; Leucht S
    Evid Based Ment Health; 2007 May; 10(2):46. PubMed ID: 17459977
    [No Abstract]   [Full Text] [Related]  

  • 31. The Role of Duloxetine in the Treatment of Depression and Associated Painful Physical Symptoms.
    Wohlreich MM; Watkin JG
    Prim Care Companion J Clin Psychiatry; 2003 Dec; 5(6):286-287. PubMed ID: 15213801
    [No Abstract]   [Full Text] [Related]  

  • 32. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample.
    Irene R; Luis MA; Helena DC; David P; Ramon DJ; Inmaculada G
    Int J Psychiatry Clin Pract; 2009; 13(2):100-8. PubMed ID: 24916728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques.
    Perahia DG; Quail D; Desaiah D; Corruble E; Fava M
    J Clin Psychiatry; 2008 Jan; 69(1):95-105. PubMed ID: 18312043
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.